Clinical efficacy and safety of cilostazol

A critical review of the literature

Kelly Rogers, Carrie S. Oliphant, Shannon Finks

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other antiplatelet agents, cilostazol does not appear to increase the rate of bleeding. Despite the possible benefit of cilostazol, its use is limited by tolerability as some patients often report drug discontinuation due to headache, diarrhea, dizziness, or increased heart rate. To date, it has been predominantly studied in the Asian population, making it difficult to extrapolate these results to a more diverse patient population. This paper discusses the evolving role of cilostazol in the treatment of vascular diseases.

Original languageEnglish (US)
Pages (from-to)377-395
Number of pages19
JournalDrugs
Volume75
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Safety
Platelet Aggregation Inhibitors
Type 3 Cyclic Nucleotide Phosphodiesterases
Hemorrhage
Cerebrovascular Disorders
Phosphodiesterase Inhibitors
Peripheral Arterial Disease
Dizziness
Percutaneous Coronary Intervention
Disease Management
Vascular Diseases
Platelet Aggregation
Population
Headache
Coronary Artery Disease
Diarrhea
Heart Rate
Placebos
cilostazol
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Clinical efficacy and safety of cilostazol : A critical review of the literature. / Rogers, Kelly; Oliphant, Carrie S.; Finks, Shannon.

In: Drugs, Vol. 75, No. 4, 01.01.2015, p. 377-395.

Research output: Contribution to journalReview article

@article{727f78e5bf84453d92a99f4146145c68,
title = "Clinical efficacy and safety of cilostazol: A critical review of the literature",
abstract = "Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other antiplatelet agents, cilostazol does not appear to increase the rate of bleeding. Despite the possible benefit of cilostazol, its use is limited by tolerability as some patients often report drug discontinuation due to headache, diarrhea, dizziness, or increased heart rate. To date, it has been predominantly studied in the Asian population, making it difficult to extrapolate these results to a more diverse patient population. This paper discusses the evolving role of cilostazol in the treatment of vascular diseases.",
author = "Kelly Rogers and Oliphant, {Carrie S.} and Shannon Finks",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s40265-015-0364-3",
language = "English (US)",
volume = "75",
pages = "377--395",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical efficacy and safety of cilostazol

T2 - A critical review of the literature

AU - Rogers, Kelly

AU - Oliphant, Carrie S.

AU - Finks, Shannon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other antiplatelet agents, cilostazol does not appear to increase the rate of bleeding. Despite the possible benefit of cilostazol, its use is limited by tolerability as some patients often report drug discontinuation due to headache, diarrhea, dizziness, or increased heart rate. To date, it has been predominantly studied in the Asian population, making it difficult to extrapolate these results to a more diverse patient population. This paper discusses the evolving role of cilostazol in the treatment of vascular diseases.

AB - Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease states, including peripheral arterial disease, cerebrovascular disease, and coronary artery disease with percutaneous coronary intervention. Overall, cilostazol appears to be a promising agent in the management of these disease states with a bleeding profile comparable to placebo; even when combined with other antiplatelet agents, cilostazol does not appear to increase the rate of bleeding. Despite the possible benefit of cilostazol, its use is limited by tolerability as some patients often report drug discontinuation due to headache, diarrhea, dizziness, or increased heart rate. To date, it has been predominantly studied in the Asian population, making it difficult to extrapolate these results to a more diverse patient population. This paper discusses the evolving role of cilostazol in the treatment of vascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=84925534331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925534331&partnerID=8YFLogxK

U2 - 10.1007/s40265-015-0364-3

DO - 10.1007/s40265-015-0364-3

M3 - Review article

VL - 75

SP - 377

EP - 395

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 4

ER -